The U.S. Food and Drug Administration (FDA) has approved PMTA applications for two Vuse brand e-cigarettes, Vibe and Ciro. However, Vuse's best-selling product, Alto, is still undergoing PMTA review.
Two models of electronic cigarettes, each with two corresponding battery types, as well as accompanying closed tobacco-flavored pods (Vibe with 3% nicotine, Ciro with 1.5% nicotine), have also been approved.
However, Vuse Vibe and Vuse Ciro flavors other than tobacco have not passed PMTA review, meaning they cannot be legally sold.
The Vuse Vibe and Ciro devices are outdated models with low sales in the market. In contrast, the NJOY Ace approved through PMTA in April is a more popular product in the market.
Earlier, two Vuse products received PMTA approval: the Vuse Solo in October 2021 and the Vuse Logic in March 2022.
Source: FDA
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.










